^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)

    i
    Other names: LAIR1, Leukocyte Associated Immunoglobulin Like Receptor 1, Leukocyte-Associated Immunoglobulin-Like Receptor 1, CD305, Leukocyte-Associated Ig-Like Receptor 1, LAIR-1, Immunoglobulin Heavy Chain Variable Region, CD305 Antigen, HLAIR1
    Associations

    News

    Trials
    2ms
    A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. (PubMed, Oncoimmunology)
    Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.
    Clinical data • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD4 (CD4 Molecule) • BTLA (B And T Lymphocyte Associated) • CCL3 (C-C Motif Chemokine Ligand 3) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    4ms
    The scavenger receptor MARCO is a ligand for the immune inhibitory receptor LAIR-1 and regulates its function in cis. (PubMed, Sci Signal)
    LAIR-1-mediated inhibitory function was increased after CRISPR-Cas9-mediated knockout of MARCO in IL-10-polarized primary human monocyte-derived macrophages. Our results identify MARCO as a regulator of LAIR-1 signaling and suggest that the induction of MARCO on immunosuppressive macrophages could enhance their function by releasing LAIR-1-mediated inhibition.
    Journal
    |
    IL10 (Interleukin 10) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    5ms
    LAIR1 prevents excess inflammatory tissue damage in Staphylococcus aureus skin infection and Cutaneous T-cell Lymphoma. (PubMed, JCI Insight)
    Underscoring the clinical relevance of our findings, CTCL skin lesions exhibited similarly increased expression in cytokine and collagen/ECM remodeling pathways, suggesting that high levels of LAIR2 promote excessive inflammatory tissue damage and compromise host defense against S. aureus infection. LAIR signaling represents a promising target for therapeutic development in CTCL and other inflammatory diseases.
    Journal
    |
    LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    5ms
    Intraepithelial Lymphocytes and LAIR1 Expression in Celiac Disease. (PubMed, Biomedicines)
    IELs exhibit a cytotoxic T-cell phenotype and were found to be CD3+, CD8+, CD103+, TCR beta+, and LAIR1+ in the small intestine control. Increased numbers of LAIR1+ IELs and lamina propria immune cells characterize CD.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • TNFRSF14 (TNF Receptor Superfamily Member 14) • GZMB (Granzyme B) • BTLA (B And T Lymphocyte Associated) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • IL4I1 (Interleukin 4 Induced 1) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    6ms
    Prognostic Signature of NETs-Related Genes in Hepatocellular Carcinoma Based on Bulk and Single-Cell Transcriptomics. (PubMed, J Hepatocell Carcinoma)
    In vitro experiments confirmed that GAS2L3 knockdown inhibited HepG2 and Huh7 cell proliferation. Integrated multi-omics analysis revealed NETs-associated prognostic signatures in HCC, with GAS2L3 identified as a key gene linking NETs to tumor progression and therapeutic potential.
    Journal
    |
    TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MUC16 (Mucin 16, Cell Surface Associated) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    TP53 mutation
    6ms
    Identification of a Novel Oxidative Stress-Based Molecular Classification and Treatment Vulnerabilities in WHO Grade 2/3 Meningiomas. (PubMed, Oncol Res)
    FOXM1 and PRNP were experimentally evidenced to be highly expressed in meningioma cells, and their knockdown hindered cell growth and migration and triggered ROS accumulation. In summary, our findings established a novel oxidative stress-based molecular classification and identified potential treatment vulnerabilities in high-grade meningiomas, which might assist personalized clinical management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • FOXM1 (Forkhead Box M1) • CD86 (CD86 Molecule) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1) • PRNP (Prion Protein)
    6ms
    LILRB4 in tumor-associated macrophage regulates macrophage polarization and glioblastoma progression via STAT3/IL10 axis. (PubMed, Gene)
    LILRB4 might functions as a critical regulator of the immunosuppressive TME in GBM by promoting M2 macrophage polarization through the STAT3/IL10 axis. Targeting LILRB4 represents a promising approach for enhancing immunotherapeutic efficacy in GBM.
    Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD163 (CD163 Molecule) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    8ms
    Targeting LAIR1-mediated immunosuppression adds a new weapon to our immunotherapy arsenal. (PubMed, J Clin Invest)
    LAIR1 KO, antibody blockade, and an immunotherapy that incorporates a LAIR1-inhibitory module into a chimeric antigen receptor (CAR) all led to increased antitumor activity by CAR T cells, reduced M2-like TAMs, altered collagen networks, and increased survival rates in mouse tumor models. These findings demonstrate an innovative immunotherapeutic approach for cancer that leverages LAIR1 inhibition to combat multiple tumor immune evasion strategies.
    Journal
    |
    LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    8ms
    CCR4-NOT Transcription Complex Subunit 7 (CNOT7) Protein and Leukocyte-Associated Immunoglobulin-like Receptor-1 in Breast Cancer Progression: Clinical Mechanistic Insights and In Silico Therapeutic Potential. (PubMed, Int J Mol Sci)
    High CNOT7 levels are associated with advanced BC stages and poor clinical outcomes, which suggests its utility as a prognostic biomarker. The inverse relationship between CNOT7 and LAIR-1 provides mechanistic insights into BC progression and immune evasion, further supported by in silico investigations.
    Journal • IO biomarker
    |
    CCR4 (C-C Motif Chemokine Receptor 4) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    HR negative
    9ms
    Blocking immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response. (PubMed, J Clin Invest)
    Enhanced antitumor responses were observed when Lair1-/- or aLAIR1 was used alone or combined with CAR T cells or when the 3-in-1 CAR T cells were used solely in chemotherapy-radiation-PD-1 blockade-resistant tumor models. These findings position LAIR1 inhibition as a promising strategy for cancer immunotherapies.
    Journal
    |
    LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    10ms
    The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion. (PubMed, Biomolecules)
    As a consequence, LAIR1 appears to play a role in some autoimmune diseases and the immune response against tumor cells. The finding of LAIR1 expression on hematological malignancies, but also on some solid tumors, could open a rationale for the targeting of this molecule to treat neoplasia, either alone or in combination with other therapeutic options.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    10ms
    NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. (PubMed, J Immunol)
    The proportion of collagen-1-positive cells was highest among tumor cells and tumor-infiltrating immune cells versus stromal immune cells, raising the potential role of tumor-associated collagen limiting immune cell infiltration into tumor. Our results support further evaluation of circulating and tumor-associated collagen products and LAIR-1 and LAIR-2 as prognostic biomarkers in advanced OC and as biomarkers for clinical response to NC410 and to other collagen- and LAIR-directed therapies.
    Journal
    |
    LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    NC410